PMID: 8611381Mar 1, 1996Paper

Recombinant human interleukin 6 in metastatic renal cell cancer: a phase II trial

British Journal of Cancer
J M StouthardC H Veenhof

Abstract

A phase II trial investigating the anti-tumour effects of recombinant human interleukin 6 (rhIL-6) in patients with metastatic renal cell cancer was carried out. RhIL-6 (150 microgram) was administered as a daily subcutaneous injection for 42 consecutive days on an outpatient basis. Forty-nine patients were studied, 12 with and 37 without previous immunotherapy. Forty patients were evaluable for response. A partial remission was noted in two patients, stable disease in 17 and progressive disease in 21. Toxicity was moderate and reversible and consisted mainly of fever, flu-like symptoms, nausea, weight loss and hepatotoxicity. Anaemia, leucocytosis and thrombocytosis and induction of acute phase protein synthesis were noted in most patients. In 15% of the patients anti-IL-6 antibodies developed, and were neutralising in only one patient. Baseline plasma IL-6 concentrations did not correlate with tumour behaviour before or after rhIL-6 treatment. In conclusion, rhIL-6 can be safely administered on an outpatient basis for prolonged period of time and has moderate, reversible toxicity. Its administration induces IL-6-antibody production in only a minority of patients. Antitmour effects of rhIL-6 in metastatic renal cancer are limi...Continue Reading

Citations

Jan 16, 2010·Annals of the New York Academy of Sciences·Steven KozlowskiRaymond P Donnelly
Apr 23, 2005·Cancer Immunology, Immunotherapy : CII·Hiroshi IshiguroHiroshi Ishikura
Jan 23, 1999·Current Opinion in Nephrology and Hypertension·K Bhagat, P Vallance
Sep 29, 2000·Urologic Oncology·J Vuky, R J Motzer
Jan 28, 1999·Leukemia Research·E Archimbaud, X Thomas
Aug 26, 1998·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·M SchulerW E Aulitzky
Aug 7, 2002·International Journal of Cardiology·Kenneth C H Fearon, Alastair G W Moses

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.

Related Papers

European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)
M SchulerW E Aulitzky
European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)
A S PlantingJ Verweij
© 2021 Meta ULC. All rights reserved